Date: 2013-08-12
Type of information: R&D agreement
Compound: biological mechanism of action of a specified GPCR drug target
Company: Duke University (USA) - the Howard Hughes Medical Institute (USA) - Lexicon Pharmaceuticals (USA) - Nuevolution (Denmark)
Therapeutic area: Technology - Services
Type agreement: R&D
Action mechanism:
Disease:
Details: * On August 12, 2013, Nuevolution has announced that it has entered into a scientific collaboration with Duke University, the Howard Hughes Medical Institute, and Lexicon Pharmaceuticals, Inc. for the investigation of the biological mechanism of action of a specified GPCR drug target. The principal investigator for Duke University and the Howard Hughes Medical Institute is Robert J. Lefkowitz, a Duke Faculty member and HHMI employee and Nobel Laureate in Chemistry 2012. During the scientific collaboration, Nuevolution will provide access to its proprietary Chemetics® technology for small molecule drug discovery and both Nuevolution and Lexicon will provide access to selected chemical libraries created using the Chemetics® technology. Within the framework of the collaboration, hundreds of millions of diverse small molecules will be screened in the endeavor to discover compounds with certain novel and unique properties against the GPCR drug target.
Financial terms:
Latest news:
